Health Care [ 3/12 ] | Biotechnology [ 26/74 ]
NASDAQ | Common Stock
Sangamo Therapeutics, Inc., a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States.
The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease.
Its preclinical development products focus on CAR-Treg cell therapies for autoimmune disorders and genome engineering for neurological diseases.
Sangamo Therapeutics, Inc. has collaborative and strategic partnerships with Biogen MA, Inc.; Kite Pharma, Inc.; Pfizer Inc.; SanofiS. A.; Novartis Institutes for BioMedical Research, Inc.; Shire International GmbH; Dow AgroSciences LLC; Sigma-Aldrich Corporation; Genentech, Inc.; Open Monoclonal Technology, Inc.; and California Institute for Regenerative Medicine.
The company was formerly known as Sangamo BioSciences, Inc. and changed its name to Sangamo Therapeutics, Inc. in January 2017.
Sangamo Therapeutics, Inc. was incorporated in 1995 and is headquartered in Richmond, California.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Nov 1, 24 | 0.04 Increased by +107.42% | -0.03 Increased by +246.00% |
| Aug 6, 24 | -0.18 Increased by +72.73% | -0.15 Decreased by -20.00% |
| May 9, 24 | -0.27 Decreased by -325.00% | -0.21 Decreased by -28.57% |
| Mar 13, 24 | -0.34 Decreased by -6.25% | -0.26 Decreased by -30.77% |
| Nov 1, 23 | -0.59 Decreased by -73.53% | -0.32 Decreased by -84.37% |
| Aug 8, 23 | -0.66 Decreased by -127.59% | -0.34 Decreased by -94.12% |
| Apr 26, 23 | 0.12 Increased by +140.00% | -0.33 Increased by +136.36% |
| Feb 22, 23 | -0.32 Decreased by -23.08% | -0.36 Increased by +11.11% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Sep 30, 24 | 49.41 M Increased by +425.77% | 10.67 M Increased by +110.25% | Increased by +21.60% Increased by +101.95% |
| Jun 30, 24 | 356.00 K Decreased by -94.79% | -36.13 M Increased by +68.45% | Decreased by -10.15 K% Decreased by -505.77% |
| Mar 31, 24 | 481.00 K Decreased by -99.70% | -49.09 M Decreased by -332.29% | Decreased by -10.21 K% Decreased by -76.38 K% |
| Dec 31, 23 | 2.04 M Decreased by -92.50% | -60.30 M Decreased by -16.01% | Decreased by -2.95 K% Decreased by -1.45 K% |
| Sep 30, 23 | 9.40 M Decreased by -64.48% | -104.16 M Decreased by -95.96% | Decreased by -1.11 K% Decreased by -451.73% |
| Jun 30, 23 | 6.83 M Decreased by -76.73% | -114.51 M Decreased by -165.23% | Decreased by -1.68 K% Decreased by -1.04 K% |
| Mar 31, 23 | 157.96 M Increased by +459.52% | 21.13 M Increased by +148.05% | Increased by +13.38% Increased by +108.59% |
| Dec 31, 22 | 27.23 M Decreased by -2.70% | -51.97 M Decreased by -38.61% | Decreased by -190.87% Decreased by -42.46% |